Healthcare Industry News: HSMN NewsFeed
News Release - December 12, 2018
Astellas Promotes Lei Ding to vice president, Payer Strategy, Contracts, and PricingNORTHBROOK, Ill., Dec. 12, 2018 -- (Healthcare Sales & Marketing Network) -- Astellas today announced that Lei Ding has been promoted to vice president, Payer Strategy, Contracts and Pricing. In this role, Ding will be responsible for leading these areas within Astellas' US business and will report to Shontelle Dodson, Pharm.D, senior vice president, Health Systems.
"Astellas is committed to collaborating with payers to ensure patients have access to our medicines," said Dodson. "Lei's background and experience in pricing and contacting strategy makes her a natural fit to undertake this responsibility and I look forward to working with her to support Astellas' portfolio."
Ding previously served as executive director of contracts and pricing at Astellas, where she led pricing and contract strategies along with contract management and negotiations for the entire Astellas portfolio in the US. Since joining Astellas in 2009, she has led multiple new product launch and lifecycle pricing strategies and value-based contract negotiations to help ensure patient access. Prior to Astellas, Ding held leadership positions in contracts and pricing, business insights, forecasting, commercial planning and portfolio management at Takeda Pharmaceuticals and TAP Pharmaceuticals.
Ding holds a master's degree in Information Systems from Northwestern University and a master of business administration degree from Washington University.
Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. For more information on Astellas, please visit our website at http://www.astellas.us. You can also follow us on Twitter at @AstellasUS, Facebook at http://www.facebook.com/AstellasUS or LinkedIn at www.linkedin.com/company/astellas-pharma.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsSeattle Genetics and Astellas Announce U.S. FDA Grants Priority Review for Enfortumab Vedotin Biologics License Application in Locally Advanced or Metastatic Urothelial Cancer
U.S. FDA Approves Supplemental New Drug Application Adding Overall Survival Data for XOSPATA(R) (gilteritinib)
Seattle Genetics and Astellas Announce Positive Topline Results from Pivotal Trial of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer